- Home
- CNTB vs MIST Comparison
CNTB vs MIST Comparison
Compare CNTB & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTB
- MIST
- Stock Information
- Founded
- CNTB 2012
- MIST 2003
- Country
- CNTB United States
- MIST Canada
- Employees
- CNTB N/A
- MIST N/A
- Industry
- CNTB Biotechnology: Pharmaceutical Preparations
- MIST Biotechnology: Pharmaceutical Preparations
- Sector
- CNTB Health Care
- MIST Health Care
- Exchange
- CNTB Nasdaq
- MIST Nasdaq
- Market Cap
- CNTB 68.5M
- MIST 81.5M
- IPO Year
- CNTB 2021
- MIST N/A
- Fundamental
- Price
- CNTB $1.17
- MIST $1.44
- Analyst Decision
- CNTB Strong Buy
- MIST Strong Buy
- Analyst Count
- CNTB 1
- MIST 3
- Target Price
- CNTB $8.00
- MIST $13.00
- AVG Volume (30 Days)
- CNTB 24.6K
- MIST 177.8K
- Earning Date
- CNTB 09-05-2024
- MIST 11-11-2024
- Dividend Yield
- CNTB N/A
- MIST N/A
- EPS Growth
- CNTB N/A
- MIST N/A
- EPS
- CNTB N/A
- MIST N/A
- Revenue
- CNTB $24,116,000.00
- MIST N/A
- Revenue This Year
- CNTB N/A
- MIST N/A
- Revenue Next Year
- CNTB $63.90
- MIST N/A
- P/E Ratio
- CNTB N/A
- MIST N/A
- Revenue Growth
- CNTB N/A
- MIST N/A
- 52 Week Low
- CNTB $0.68
- MIST $1.12
- 52 Week High
- CNTB $2.84
- MIST $3.52
- Technical
- Relative Strength Index (RSI)
- CNTB 44.02
- MIST 42.50
- Support Level
- CNTB $1.18
- MIST $1.41
- Resistance Level
- CNTB $1.26
- MIST $1.53
- Average True Range (ATR)
- CNTB 0.07
- MIST 0.07
- MACD
- CNTB -0.01
- MIST -0.01
- Stochastic Oscillator
- CNTB 13.59
- MIST 26.96
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).